Pyrazolone derivatives as PDE4 inhibitors

US9090597B2 · kind B2 · utility

Assignee

• TAKEDA GMBH · DE

Inventors

• Beate Schmidt · Allensbach, DE
• Christian Scheufler · Bad Liebenzell, DE
• Jürgen Volz · Radolfzell, DE
• Martin Feth · Kelkheim, DE
• Rolf-Peter Hummel · Radolfzell, DE
• Armin Hatzelmann · Konstanz, DE
• Christof Zitt · Konstanz, DE
• Andrea Wohlsen · Konstanz, DE
• Degenhard Marx · Radebeul, DE
• Hans-Peter Kley · Allensbach, DE
• Deborah Ockert · Hamburg, DE
• Anke Heuser · Hamburg, DE
• Johannes A. M. Christiaans · Lelystad, NL
• Geert Jan Sterk · Utrecht, NL
• Wiro M. P. B. Menge · Oosterbeek, NL

Key dates

• Filing date: Aug 29, 2014
• Grant date: Jul 28, 2015
• Expiry date: Aug 29, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase useful in the treatment of psoriasis or atopic dermatitis.